KENNETH JAMES HOLROYD
Medical Practice in Collegeville, PA
License number
Pennsylvania MD425629
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Collegeville, PA 19426
Personal information
See more information about KENNETH JAMES HOLROYD at radaris.comName
Address
Phone
112 S Mennonite Rd, Collegeville, PA 19426
Ambler, PA
112 Mennonite Rd, Collegeville, PA 19426
112 S Mennonite Rd, Collegeville, PA 19426
701 Moore Ave, Lewisburg, PA 17837
Professional information
Method Of Treating Asthma Using Soluble Il-9 Receptor Variants
US Patent:
6602850, Aug 5, 2003
Filed:
Jun 16, 2000
Appl. No.:
09/596377
Inventors:
Roy Clifford Levitt - Ambler PA
Luigi Grasso - Philadelphia PA
Nicholas C. Nicolaides - Boothwyn PA
Kenneth J. Holroyd - Collegeville PA
Luigi Grasso - Philadelphia PA
Nicholas C. Nicolaides - Boothwyn PA
Kenneth J. Holroyd - Collegeville PA
Assignee:
Genaera Corporation - Plymouth Meeting PA
International Classification:
A61K 3816
US Classification:
514 12, 514 2, 514 8, 514826, 514885
Abstract:
This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 173. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.
Nucleic Acid Encoding An Interleukin-9 Receptor Variant
US Patent:
7384767, Jun 10, 2008
Filed:
Jan 31, 2007
Appl. No.:
11/700260
Inventors:
Roy Clifford Levitt - Ambler PA, US
Luigi Grasso - Philadelphia PA, US
Nicholas C. Nicolaides - Boothwyn PA, US
Kenneth J. Holroyd - Collegeville PA, US
Luigi Grasso - Philadelphia PA, US
Nicholas C. Nicolaides - Boothwyn PA, US
Kenneth J. Holroyd - Collegeville PA, US
Assignee:
Genaera Corporation - Plymouth Meeting PA
International Classification:
C12N 5/10, C12N 15/12, C12N 15/63
US Classification:
435 691, 435325, 4353201, 435 711, 536 235
Abstract:
This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.
Nucleic Acid Encoding An Interleukin-9 Receptor Variant
US Patent:
7208292, Apr 24, 2007
Filed:
Mar 9, 2006
Appl. No.:
11/371157
Inventors:
Roy Clifford Levitt - Ambler PA, US
Luigi Grasso - Philadelphia PA, US
Nicholas C. Nicolaides - Boothwyn PA, US
Kenneth J. Holroyd - Collegeville PA, US
Luigi Grasso - Philadelphia PA, US
Nicholas C. Nicolaides - Boothwyn PA, US
Kenneth J. Holroyd - Collegeville PA, US
Assignee:
Genaera Corporation - Plymouth Meeting PA
International Classification:
C12N 5/10, C12N 15/12, C12N 15/63
US Classification:
435 691, 435 711, 435 712, 435325, 4352523, 43525411, 4353201, 536 235
Abstract:
This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.
Nucleic Acids Encoding Interleukin-9 Receptor Variants
US Patent:
7056698, Jun 6, 2006
Filed:
Dec 17, 2002
Appl. No.:
10/320646
Inventors:
Roy Clifford Levitt - Ambler PA, US
Luigi Grasso - Philadelphia PA, US
Nicholas C. Nicolaides - Boothwyn PA, US
Kenneth J. Holroyd - Collegeville PA, US
Luigi Grasso - Philadelphia PA, US
Nicholas C. Nicolaides - Boothwyn PA, US
Kenneth J. Holroyd - Collegeville PA, US
Assignee:
Genaera Corporation - Plymouth Meeting PA
International Classification:
C12N 5/10, C12N 15/12, C12N 15/63
US Classification:
435 691, 435471, 435 701, 435325, 4352523, 43525411, 4353201, 536 235
Abstract:
This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 173. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.
Interleukin-9 Receptor Mutants
US Patent:
2011022, Sep 15, 2011
Filed:
Apr 1, 2010
Appl. No.:
12/752219
Inventors:
Roy Clifford Levitt - Ambler PA, US
Luigi Grasso - Philadelphia PA, US
Nicholas C. Nicolaides - Boothwyn PA, US
Kenneth J. Holroyd - Collegeville PA, US
Luigi Grasso - Philadelphia PA, US
Nicholas C. Nicolaides - Boothwyn PA, US
Kenneth J. Holroyd - Collegeville PA, US
International Classification:
C07K 14/715, C07H 21/04, C07H 21/02
US Classification:
530350, 536 235
Abstract:
This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.
Interleukin-9 Receptor Mutants
US Patent:
7704710, Apr 27, 2010
Filed:
May 7, 2008
Appl. No.:
12/116706
Inventors:
Roy Clifford Levitt - Ambler PA, US
Luigi Grasso - Philadelphia PA, US
Nicholas C. Nicolaides - Boothwyn PA, US
Kenneth J. Holroyd - Collegeville PA, US
Luigi Grasso - Philadelphia PA, US
Nicholas C. Nicolaides - Boothwyn PA, US
Kenneth J. Holroyd - Collegeville PA, US
Assignee:
Genaera Corporation - Plymouth Meeting PA
International Classification:
C12N 5/10, C12N 15/24, C12N 15/63, C12N 15/64
US Classification:
435 6952, 4352523, 4353201, 435325, 536 2351
Abstract:
This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.